What the FDA labels say about taking them together
Ivabradine and nirmatrelvir/ritonavir
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names ivabradine in its contraindications section; the ivabradine label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Drug Class: ivabradine; Drugs within Class: ↑ ivabradine; Effect on Concentration: Co-administration with ivabradine is contraindicated due to potential for bradycardia or conduction disturbances.”
Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the ivabradine label say about nirmatrelvir/ritonavir?
Ivabradine's label (effective November 10, 2025) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed
What does the nirmatrelvir/ritonavir label say about ivabradine?
Nirmatrelvir/ritonavir label, contraindicationsCardiovascular agents: eplerenone, ivabradine
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: ivabradine; Drugs within Class: ↑ ivabradine; Effect on Concentration: Co-administration with ivabradine is contraindicated due to potential for bradycardia or conduction disturbances [see ].
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ivabradine | Nirmatrelvir/ritonavir | |
|---|---|---|
| Labeled for | Heart failure | COVID-19 |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.761 per tablet 5 mg tablet | $49.24 per unit 300-100 mg dose pack |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once